Ivan Marc / Shutterstock.com
2 October 2025NewsAmericasMarisa Woutersen

IP agencies vital to pharma and biotech grind to a halt

From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 September 2025   Sweeping tariffs send shockwaves through the pharma sector, as experts warn of consumer detriment and supply chain risks.
Americas
9 September 2025   Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.
Americas
6 March 2025   Return-to-office orders, redundancies, hiring freezes—do changes sweeping through the US agency ‘risk breaking the system’? Marisa Woutersen finds patent practitioners fearful of the future.